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Bovine papillomavirus type 2 (BPV-2) infection has been associated with urinary bladder tumours
in adult cattle grazing on bracken fern-infested land. In this study, we investigated the
simultaneous presence of BPV-2 in whole blood and urinary bladder tumours of adult cattle in an
attempt to better understand the biological role of circulating BPV-2. Peripheral blood samples
were collected from 78 cattle clinically suffering from a severe chronic enzootic haematuria.
Circulating BPV-2 DNA was detected in 61 of them and in two blood samples from healthy cows.
Fifty of the affected animals were slaughtered at public slaughterhouses and neoplastic
proliferations in the urinary bladder were detected in all of them. BPV-2 DNA was amplified and
sequenced in 78% of urinary bladder tumour samples and in 38.9% of normal samples as a
control. Circulating episomal BPV-2 DNA was detected in 78.2% of the blood samples.
Simultaneous presence of BPV-2 DNA in neoplastic bladder and blood samples was detected in
37 animals. Specific viral E5 mRNA and E5 oncoprotein were also detected in blood by RT-PCR
and Western blot/immunocytochemistry, respectively. It is likely that BPV-2 can persist and be
maintained in an active status in the bloodstream, in particular in the lymphocytes, as a reservoir of
viral infection that, in the presence of co-carcinogens, may cause the development of urinary
bladder tumours.
INTRODUCTION
Bovine papillomaviruses (BPVs) are species-specific, dou-
ble-stranded DNA viruses responsible for cutaneous and
mucosal neoplastic lesions. They are small non-enveloped
viruses with an icosahedral capsid. Their open reading
frames (ORFs) are divided into early (E) and late (L)
regions. The early region encodes non-structural proteins
E1 to E7, of which, E5, E6 and E7 are known to be
oncoproteins. The late region encodes structural proteins
L1 and L2 forming the capsid. Bovine papillomavirus type
2 (BPV-2) is classified in the genus Deltapapillomavirus,
species 4, the biological properties of which are character-
ized by the induction of fibropapillomas in cattle and
sarcoids in equids (Brandt et al., 2008; Chambers et al.,
2003; de Villiers et al., 2004). BPV-2 infection in the
presence of environmental carcinogens, such as ptaquilo-
side (PT) of bracken fern (Pteridium aquilinum), has been
associated with urinary bladder neoplastic lesions in adult
cattle, in which chronic enzootic haematuria (CEH) is the
most important clinical sign (Campo, 1997; Campo et al.,
1992; Hopkins, 1986).
The effect of the route of viral infection, and the synergistic
relationship between BPV-2 and immunosuppressive and
oncogenic compounds present in the bracken fern in the
malignant progression of bladder lesions (Campo, 1997;
Campo et al., 1992; Jarrett et al., 1978; Reddy & Fialkow,
1983; Stocco dos Santos et al., 1998) are not well-known,
thus deserving further investigations.
To date, the BPV-2 genome has been detected in
lymphocytes during latent papillomavirus infection in
cattle (Campo et al., 1994). In addition, the occurrence
of horizontal transmission of BPV-2 has been reported in
healthy cattle experimentally inoculated with peripheral
blood from haematuric animals (Stocco dos Santos et al.,
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1998). More recently, BPV-2 DNA was detected in seven of
12 urinary bladders and 10 of 14 blood samples obtained
from Brazilian cattle suffering from CEH. No histological
diagnosis of any tumours was performed. In addition,
BPV-2 was also detected in one urinary bladder and in one
whole blood sample from asymptomatic cattle (Wosiacki
et al., 2005).
In an attempt to gain insights into understanding the role
and significance of BPV-2 presence in the blood stream, an
analysis of blood samples was carried out on a large
number of haematuric cattle grazing on bracken fern-
infested lands, where urinary bladder tumours occur
endemically (Borzacchiello et al., 2003).
METHODS
Blood and bladder samples. Blood samples from 78 cows with
clear clinical signs of chronic haematuria and from 14 healthy 4- to 8-
year-old control cows were collected; both groups were the same
Podolica breed and shared grazing lands. A post-mortem examination
was carried out on 50 of the haematuric animals following slaughter
at public slaughterhouses. Most of them appeared to be cachectic,
showing a metabolic state characterized by weight and muscle loss as
well as anaemia and they were not fit for human consumption.
Eighteen bladder samples from healthy animals were also collected in
the same way.
Samples of neoplastic and control bladder mucosa were split in two.
One half was immediately fixed in 10% neutral formalin and
embedded in paraffin. Ticked sections (5 mm) were cut and stained
with haematoxylin and eosin. Neoplastic lesions were classified
according to the criteria reported in the recent World Health
Organization (WHO) Blue Book on the pathology and genetics of
tumours of the urinary system and male genital organs in humans
(Lopez-Beltran et al., 2004; Sauter et al., 2004). Tumours of the
urinary bladder in cattle share many morphological similarities to
their human counterparts, and the WHO histological classification
appears to encompass all microscopic patterns of the urinary bladder
tumours observed in cattle (Roperto et al., 2007). The other half of
the sample was immediately frozen in liquid nitrogen and stored in
dry ice.
BPV-2 DNA detection and sequencing. Unfractionated whole
blood samples and frozen samples of bladder tumours were analysed
by PCR as described previously (Borzacchiello et al., 2003). Briefly,
venous blood was collected in heparinized vacutainers (BD
Biosciences) and then stored at 4 uC; DNA was extracted with
QIAamp DNA mini kit (Qiagen) according to the manufacturer’s
instructions. Frozen bladder samples were minced and incubated
at 55 uC overnight with 60 mg proteinase K ml21 in the appro-
priate buffer (Manos et al., 1989) and then at 95 uC for 10 min to
inactivate the enzyme. Each sample (10 ml) was amplified in
50 ml reaction mixture containing 3 mM MgCl2, 1 U Platinum Taq
(Invitrogen), 25 pmol each primer and 200 mM dNTPs. The reaction
was carried out in an iCycler (Bio-Rad Laboratories) using
forward (59-TTGCTGCAATGCAACTGCTG-39) and reverse (59-
TCATAGGCACTGGCACGTT-39) primers that amplify a DNA
fragment encompassing part of the E5 and L2 open reading frame
(ORF) of BPV-1 (311 bp, from nt 3915 to 4226) and BPV-2 (306 bp,
from nt 3919 to 4225) (Otten et al., 1993). PCR conditions were as
follows: denaturation for 3 min at 95 uC, followed by 35 cycles of
denaturation at 95 uC for 45 s, annealing at 50 uC for 45 s and
extension at 72 uC for 1 min. The final PCR products were
electrophoresed in 2% agarose gel and visualized by ethidium
bromide staining.
To confirm the PCR data, the amplified band was excised from the gel
and purified through silicagel membranes by using the QIAquick PCR
quantification kit, according to the manufacturer’s instructions
(Qiagen). Then, the amplified DNA was subjected to direct
sequencing in an automated apparatus (Biogen).
Detection of circular BPV-2 DNA. BPV-2-positive DNA samples
from tissues and blood were analysed by rolling-circle amplification
(RCA) according to the method developed by Rector et al. (2004).
The multiple-primed RCA is a method that utilizes the W29 DNA
polymerase with random hexamer primers to amplify the complete
circular genome of papillomaviruses without the need for prior
knowledge of their DNA sequences. Briefly, multiple-primed RCA
was performed with the TempliPhi 100 amplification kit (Amersham
Biosciences) according to the manufacturer’s instructions. Extracted
DNA (2 mg) was transferred into a 0.5 ml tube with 5 ml TempliPhi
sample buffer containing 450 mM extra dNTPs, and 0.2 ml TempliPhi
enzyme mix containing the W29 DNA polymerase and exonuclease-
protected random hexamers in 50% glycerol. The samples were
denatured at 95 uC for 3 min and then placed on ice. The reaction
mixtures were incubated overnight (approx. 16 h) at 30 uC.
Afterwards, the reaction mixtures were placed on ice, subsequently
heated to 65 uC for 10 min to inactivate the W29 DNA polymerase,
and stored at 220 uC until further analysis. The multiply primed
RCA products (2 ml) were digested with 10 U EcoRI, a single cutter of
the BPV-2 complete genome, and resolved in an ethidium bromide-
stained agarose gel. As a negative control, water was amplified by
multiple primed RCA and 2 ml was digested with EcoRI.
BPV-2 mRNA in blood samples. Blood samples were collected from
15 animals with cancer and stored in PAXgene blood RNA tubes
(Qiagen) containing a proprietary reagent that immediately stabilizes
intracellular RNA. Purification of total RNA from bovine whole blood
was performed with the PAXgene blood RNA kit (Qiagen) according
to the manufacturer’s instructions. RNA (300 ng) was reverse
transcribed using the Superscript III First Strand kit (Invitrogen) in
a final volume of 20 ml. To rule out the presence of contaminating
DNA in RNA samples, all the assays were performed both with and
without reverse transcriptase. The synthesized cDNA was analysed
by PCR with specific primers for the E5 ORF (forward primer,
59-CACTGCCATTTGTTTTTTTC-39; reverse primer, 59-GGAGCAC
TCAAAATGATCCC-39) using the PCR conditions described above,
but using an annealing temperature of 48 uC. The final amplified
products were electrophoresed in a 2% agarose gel and visualized by
ethidium bromide staining. The amplified band was excised from the
gel and subjected to direct sequencing as above.
Protein isolation and E5 expression. Fifteen bladder samples
stored in dry ice were homogenized in lysis buffer containing 50 mM
Tris/HCl pH 7.5, 150 mM NaCl, 1% Triton X-100. Immediately
prior to use, the following were added: 1 mM DTT, 2 mM PMSF,
1.7 mg Aprotinin ml21, 25 mM NaF, 1 mM Na3VO4 (Sigma-
Aldrich) by Ultra-turrax T8 Ika-Werke. The proteins were removed
by centrifugation at 12 300 g for 30 min at 4 uC. The protein
concentration was measured using the Bradford assay (Bio-Rad).
Blood samples (30 ml) were harvested from cattle suffering from
chronic enzootic haematuria. An equal volume of 16 PBS was added
to the blood and the resulting solution was transferred on a 2 : 1 Ficoll
gradient (Biochrom AG). After centrifugation at 352 g for 20 min at
room temperature, the recovered lymphocytes were homogenized
with 50 ml lysis buffer (described above for bladder samples).
The protein concentration was measured using the Bradford assay
(Bio-Rad).
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Proteins derived from tissues (1 mg) or from lymphocytes (500 mg)
were immunoprecipitated by using 2 mg antibody anti-E5 (a kind gift
from Dr M. S. Campo, University of Glasgow, Scotland) and 30 ml G-
Sepharose (GE Healthcare). Immunoprecipitates were washed four
times in complete lysis buffer (above), finally we added 46 LDS
loading buffer (Invitrogen) and then heated at 70 uC for 10 min.
Immunoprecipitates were separated on 4–12% polyacrylamide gels
and transferred to nitrocellulose filter membranes (Bio-Rad) for 16 h
at 25 mA in 192 mM glycine/25 mM Tris-HCl (pH 7.5)/10%
methanol. Membranes were blocked for 1 h at room temperature in
5% non-fat dried milk and incubated with primary antibody
overnight at 4 uC. After three washes in Tris-buffered saline,
membranes were incubated with rabbit anti-sheep IgG–horseradish
peroxidase (HRP) (Santa Cruz) for 30 min at room temperature.
Proteins were visualised by enhanced chemiluminescence (Amersham
Biosciences).
Cytospin preparations and immunocytochemistry. Blood from
cows with haematuria was collected in heparin-coated tubes. Blood
(100 ml) was lysed with 700 ml erythrocyte lysis buffer containing
0.8% ammonium chloride and then leukocytes were washed twice by
centrifugation at 250 g in 1% PBS. A 100 ml aliquot of each sample
was put into the appropriate well of a cytospin chamber (Thermo
Scientific) and centrifuged at 164 g for 5 min at 4 uC. After fixing in
methanol, slides were blocked for endogenous peroxidase activity in
0.3% H2O2 in methanol for 20 min. Slides were then incubated
overnight at room temperature in a humidified chamber with a 1 : 500
dilution of polyclonal sheep anti-E5 antibody (kindly provided by Dr
M. S. Campo). The slides were washed three times with PBS, then
incubated for 30 min with a 1 : 100 dilution of the appropriate
biotinylated rabbit anti-sheep IgG (Santa Cruz). They were washed
three times with PBS and then incubated with streptavidin-
conjugated HRP (LSAB kit; DakoCytomation). Colour was developed
by treatment with diaminobenzidine (DakoCytomation) for 5–
20 min. Sections were counterstained with Mayer’s haematoxylin.
RESULTS
Microscopic patterns
Neoplastic lesions were detected in the urinary bladder of all
of the slaughtered animals. Flat lesions were observed in six
animals, papillary proliferations were detected in 25 animals
and the remaining 19 cattle had invasive tumours. In the last
group, polypoid, ulcerated and/or sessile mucosal lesions
were also manifest. Five of the flat lesions showed histological
patterns of carcinoma in situ and one of urothelial dysplasia;
endoluminal proliferations included three urothelial papil-
lomas, four papillary urothelial neoplasms of low malignant
potential, nine low-grade urothelial carcinomas and six high-
grade urothelial carcinomas. In addition, two adenocarcino-
mas (enteric type) and only one squamous cell carcinoma
were seen. Invasive tumours showed the histological features
of low-grade invasive carcinomas (six cases), high-grade
invasive carcinomas (ten cases), the nested variant of
urothelial carcinomas (two cases) and a sarcomatoid
carcinoma (one case).
BPV-2 DNA detection
PCR analysis, validated by direct sequencing of the
amplified product, demonstrated the presence of true
BPV-2 sequences; only the sequenced samples were defined
as being positive. BPV-2 sequences were detected in 39 of
the 50 tumour samples (78% of examined cases) and in
seven of 18 normal bladder control samples (39% of the
examined cases). In contrast, none of the analysed samples
showed the presence of BPV-1 sequences. The difference in
the presence of BPV-2 DNA between pathological and
normal samples was highly significant (Fisher’s exact test,
P,0.004), suggesting a strong association of BPV infection
with bladder tumours. Direct sequencing detected some
false-positive samples arising from bovine genomic
sequences (about 2% of all analysed samples), as reported
previously (Borzacchiello et al., 2003).
BPV-2 sequences were detected in 61 of 78 blood samples
of haematuric animals (78.2% of the examined samples)
and in two of 14 healthy samples (~14.2% of the examined
samples) (Fig. 1a). The difference in the presence of BPV-2
DNA between pathological and normal blood samples was
highly significant (Fisher’s exact test, P,0.001).
The data from the PCR and direct sequencing showed a
high (94.87%) concordance between positive blood and
bladder samples in the 50 animals suffering from bladder
tumours
Sequence analysis
Sequence analyses of the positive bladder and blood
samples from the same animal were done using CLUSTAL
W (http://www.ebi.ac.uk/clustalw/) and BLAST [http://
Fig. 1. PCR of blood samples. (a) DNA extracted from whole
blood samples from healthy animals (lanes 1–5) and those with
cancer (lanes 6–11) was subjected to PCR amplification with
primers for BPV. The 310 bp amplification products were
visualized in an ethidium-bromide-stained 2% agarose gel. +,
DNA from a recombinant plasmid for BPV-2; ”, no DNA; M8,
molecular mass marker type VIII (Roche), sizes given to the right
(bp). (b) RT-PCR of total RNA from whole blood of healthy animals
(lanes 2 and 5) or those with BPV-2-positive bladder tumours
(lanes 1, 3 and 4). The length of the E5 amplification product was
150 bp. +, DNA from a BPV-2-positive bladder tumour; ”, no
cDNA; M8, molecular mass marker type VIII (Roche), sizes given to
the left (bp).
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www.ncbi.nlm.nih.gov/BLAST (Altschul et al., 1997)]
programs. This revealed the presence of DNA sequences
matching the BPV-2 complete genome from the GenBank
database, and in one case revealed the presence of two
mutations in the non-coding region between the E5 and L2
genes (Supplementary Fig. S1, available in JGV Online).
Alignment of this DNA sequence with those in the database
revealed that the same mutations were present in the DNA
sequence of a BPV-2 isolate from Hungarian equine
sarcoids (GenBank accession number AF102551).
BPV-2 physical status and mRNA expression
Episomal (circular) forms of the BPV DNA were detected
in 39 bladder tumour and blood samples collected from the
same animals by using the multiple primed RCA (Fig. 2).
Samples were digested with EcoRI, which recognizes a
single cut site in the BPV-2 genome, and the detection of a
single ~8000 bp band indicated the presence of episomal
forms. Despite the fact that this was a non-quantitative
method, it is noteworthy that the band intensity of circular
BPV DNA recovered from blood samples was always lower
than that detected in tumour samples. Unfortunately, RNA
from these samples was not available for the detection of
viral transcripts, so we were unable to verify the expression
of the viral genes. Nevertheless, the presence of viral
transcripts for the E5 ORF was detected in two of three
blood samples from other animals with BPV-2-positive
bladder tumours (Fig. 1b).
Presence of the BPV-2 E5 oncoprotein
Western blot analysis showed the presence of E5 protein in
neoplastic tissues (Fig. 3a) and in peripheral blood cells
from animals with cancer (Fig. 3b). Analysis of cytospin
preparations of peripheral blood leukocytes from infected
animals demonstrated a strong cytoplasmic E5 immuno-
reactivity in numerous lymphocytes (Fig. 4). No E5
oncoprotein expression was detected in healthy animals.
DISCUSSION
This study focused on the presence of BPV-2 in the blood
of a large number of haematuric cattle suffering from
urinary bladder tumours. The results of PCR analyses,
confirmed by direct sequencing, also revealed the presence
of false positive samples, probably because the primers
represent consensus sequences devised to amplify genomic
sequences of different BPVs (i.e. BPV-1 and BPV-2). It has
been suggested that the use of consensus primers may
Fig. 2. Detection of circular BPV-2 DNA in bladder and blood
samples by RCA. DNA was processed as in Methods and the
amplified products were digested with EcoRI. Lanes: 1–5, DNA
from BPV-2 infected animals; b, DNA from blood sample; t, DNA
from bladder sample; M, molecular mass marker type II (Roche),
sizes given to the right (bp); n, negative control consisting of water
amplified by multiple primed RCA that was digested with EcoRI.
Fig. 3. Western blot analysis of E5 protein from neoplastic
bladder tissues and peripheral blood cells. (a) Lanes 1–6,
neoplastic tissues; lanes 7–8 healthy animals. (b) Lanes 1–6,
blood from animals with cancer; lane 7, blood from a healthy
animal.
Fig. 4. Detection of cytoplasmic E5 in lymphocyte cells from
cytospin preparations of PBMCs. Samples were incubated with
sheep anti-E5, then rabbit anti-sheep IgG followed by streptavidin-
conjugated HRP. Diaminobenzidine was used for colour devel-
opment and samples were stained with haematoxylin.
Magnification, 550.
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increase the possibility of amplifying non-specific
sequences, as is the case for the MY09/11 primers for
human papillomavirus (Fernandez-Contreras et al., 2000).
These facts should be taken into account when evaluating a
positive result from a PCR using consensus primers if this
is the only diagnostic method used. In this analysis, only
sequenced samples were considered; this revealed the
presence of BPV-2 in whole blood samples. Moreover,
RCA analysis suggested that the complete genome of BPV-
2 was present in circular form in blood samples as well as
in bladder tumours.
Our data on a large number of animals with histologically
confirmed neoplastic disease not only clearly corroborate
previous reports (Campo et al., 1994; Stocco dos Santos
et al., 1998; Wosiacki et al., 2005) but also raise a number
of questions about the source, role and significance of the
presence of BPV DNA and viral oncoproteins in blood.
The simultaneous presence of BPV-2 DNA sequences in
most of the blood and bladder tumour samples suggests
that BPV-2 DNA could be derived from common sources,
thus implying that the virus might spread via a haemato-
genous route. Recently, human papillomavirus (HPV)
DNA was detected in peripheral blood mononuclear cells
(PBMCs) obtained from paediatric patients and healthy
blood donors. It has been speculated that PBMCs may
serve as a source of HPV in the infection of epithelial cells
(Bodaghi et al., 2005). If this is also the case in cattle, BPV-
2 could reach the urothelial tissue not only from the
paragenital area, as already suggested (Campo, 2002), but
also via the blood stream, and could become involved in
urinary bladder tumour development independently or
jointly with several biological and/or chemical co-factors.
PT, the major carcinogen of the bracken fern, is activated
in alkaline environments such as the urine of herbivores
(Borzacchiello et al., 2006; Prakash et al., 1996), it then
appears to act synergistically with BPV-2, thus resulting
ultimately in tumours of the urinary bladder in cattle.
Recently, BPV DNA was simultaneously detected in
different tissues of the same animals, thus suggesting a
haematogenous virus spread (Freitas et al., 2007). In our
study, the detection of circulating BPV DNA in only a
limited number of healthy cattle that share grazing lands
with animals with cancer suggests the plausibility of this
hypothesis. We not only detected circulating BPV DNA
sequences but also showed the presence of episomal DNA
by RCA analysis. The presence of circular BPV DNA
implies that at least E1 and E2 proteins are expressed, as
they are absolutely required for the maintenance and
replication of the episomal BPV DNA (Tonon et al., 2001).
Moreover, mRNAs encoding the E5 gene were detected in a
number of blood samples from animals suffering from
BPV-positive bladder tumours. In addition to this, the E5
oncoprotein was detected in the blood of 13 of 15 cows
suffering from urothelial tumours, in which E5 expression
was documented in immunocytochemical analysis. Taken
together, these data may indicate a biological activity of
BPV-2 in the blood of these animals, reinforcing the
hypothesis that the bloodstream may work as reservoir for
BPV infection. In particular, it appears that lymphocytes
are infected by BPV-2, as clearly demonstrated by the
strong immunocytochemical positivity for the E5 protein.
An alternative explanation for circulating BPV DNA is that
it might, at least in part, originate from primary bladder
tumours. The presence of viral DNA in the peripheral
blood fraction (PBF), plasma and serum is not an unusual
event in tumour patients. Recently, HPV DNA was
detected in serum and/or PBF of individuals with cervical,
head/neck or schistosomiasis-associated bladder cancer
(Yang et al., 2005) and women suffering from cervical
carcinomas (Ho et al., 2005; Widschwendter et al., 2003). It
has been postulated that HPV DNA is involved in
carcinogenesis in breast tissue in some patients suffering
from cervical cancer (Widschwendter et al., 2004). Very
recently, sequences of the HPV types 16 and 18, known to
be involved in cervical carcinogenesis, were detected in 86
and 48% of breast cancer samples, respectively (de Villiers
et al., 2005; Kan et al., 2005). It is noteworthy that HPV
DNA has been detected both in lung and breast cancers of
patients with a history of cervical cancer, thus suggesting
that HPV DNA might be transported from the original site
of infection to pulmonary and breast tissues by the
bloodstream and subsequently be involved in secondary
tumour development (Cheng et al., 2001; Widschwendter
et al., 2004). However, it is well-known that urinary
bladder cancers in cattle are characterized by a relatively
low incidence of apparent metastases (about 8–10%)
(Pamukcu et al., 1976; Roperto et al., 2005). In addition,
non-metastatic tumours in other organs of cattle with a
history of urothelial cancer are known to occur very rarely.
Therefore, it is reasonable to suggest that if the presence of
BPV-2 E5 oncoprotein in PBMC is the result of a passive
spread, the oncoprotein doesn’t appear to play an
important role in neoplastic events in distant organs.
However, detection of E5 in blood may be utilized as an
additional diagnostic and/or prognostic marker and as a
target for introducing immunotherapeutic procedures to
reduce deaths and economic losses due to BPV activity.
In conclusion, we provide evidence that BPV-2 may persist
and be maintained in a replicative status in the blood-
stream, in particular in the lymphocytes, and act as a
reservoir of viral infection that in the presence of biological
and/or chemical co-carcinogens can be involved in bladder
tumour development.
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